Scynexis Drug Patent Portfolio
Scynexis owns 1 orange book drug protected by 5 US patents Given below is the list of Scynexis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11534433 | Antifungal agents with enhanced activity in acidic pH | 10 Jun, 2039 | Active |
| US10174074 | Salts and polymorphs of SCY-078 | 19 Jan, 2035 | Active |
| US10370406 | Salts and polymorphs of SCY-078 | 19 Jan, 2035 | Active |
| US10927142 | Salts and polymorphs of SCY-078 | 19 Jan, 2035 | Active |
| US8188085 | Antifungal agents | 28 Aug, 2030 | Active |
Latest Legal Activities on Scynexis's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Scynexis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Jul, 2024 | US10927142 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8188085 |
| transaction for FDA Determination of Regulatory Review Period | 28 Feb, 2024 | US8188085 |
| Second letter to regulating agency to determine regulatory review period | 21 Dec, 2023 | US8188085 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Nov, 2023 | US8188085 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Oct, 2023 | US8188085 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Feb, 2023 | US10370406 |
|
Recordation of Patent Grant Mailed
Critical
| 27 Dec, 2022 | US11534433 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 27 Dec, 2022 | US11534433 |
|
Issue Notification Mailed
Critical
| 07 Dec, 2022 | US11534433 |
|
Application Is Considered Ready for Issue
Critical
| 22 Nov, 2022 | US11534433 |
| Dispatch to FDC | 22 Nov, 2022 | US11534433 |
|
Issue Fee Payment Verified
Critical
| 18 Nov, 2022 | US11534433 |
|
Issue Fee Payment Received
Critical
| 18 Nov, 2022 | US11534433 |
| Initial letter Re: PTE Application to regulating agency | 25 Aug, 2022 | US8188085 |
Scynexis's Family Patents
Scynexis Drug List
Given below is the complete list of Scynexis's drugs and the patents protecting them.
1. Brexafemme
Brexafemme is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11534433 | Antifungal agents with enhanced activity in acidic pH |
10 Jun, 2039
(14 years from now)
| Active |
| US10174074 | Salts and polymorphs of SCY-078 |
19 Jan, 2035
(9 years from now)
| Active |
| US10370406 | Salts and polymorphs of SCY-078 |
19 Jan, 2035
(9 years from now)
| Active |
| US10927142 | Salts and polymorphs of SCY-078 |
19 Jan, 2035
(9 years from now)
| Active |
| US8188085 | Antifungal agents |
28 Aug, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brexafemme's drug page